Omlonti was launched internationally in 2018, and is used in five countries worldwide.
It has shown success in reducing intraocular pressure by 5 to 7 millimeters of mercury over a 12-month period, according to the company.
“This approval is an important milestone in our ambition to tackle unmet needs in eye health and advances our goal of realization of ‘Happiness with Vision’. It also represents our first glaucoma offering in the U.S.,” Peter Sallstig, MD, chief medical officer at Santen, said in a Sept. 26 press release. “We are pleased to provide doctors and patients in the U.S. with a new option to help control intraocular pressure for the more than three million Americans affected by glaucoma or ocular hypertension.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.